# US 2021/0330824 A1 · Purification method and compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330824 A1
- Document ID: US20210330824A1
- Status: Published application
- Kind: A1
- Application number: 17/314,158
- Filed: 2021-05-07
- Published: 2021-10-28
- Earliest claimed: 2013-12-18
- Assignees: Ge Healthcare Limited
- Applicants: GE Healthcare Limited
- Inventors: Torgrim Engell; Andreas Meijer; Imtias Ahmed Khan; Robert James Nairne; Graeme McRobbie
- Web page: https://patentgrep.com/patent/US20210330824A1

## CPC

- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61K 51/04: Organic compounds
- A61K 51/121: {Solutions, i.e. homogeneous liquid formulation}
- B01D 15/20: relating to the conditioning of the sorbent material
- B01D 15/22: relating to the construction of the column
- B01D 15/325: {Reversed phase}
- B01D 15/426: {Specific type of solvent}
- C07B 59/00: Introduction of isotopes of elements into organic compounds {; Labelled organic compounds per se}
- C07B 59/001: {Acyclic or carbocyclic compounds}
- C07B 63/00: Purification; Separation (separation of optically-active compounds C07B57/00); Stabilisation; Use of additives
- C07K 1/13: Labelling of peptides
- C07K 1/145: {by extraction or solubilisation}
- C07K 14/001: {by chemical synthesis}
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to a method of purifying a radiotracer which comprises 18F-labelled aminoxy-functionalised biological targeting moiety. The invention provides radioprotectant-containing radiopharmaceutical compositions of the tracers, as well as associated automated methods and cassettes.

## Claims

### Claim at position 1

1-19. (canceled)

### Claim 20

A method of purification of a radiotracer which comprises the following steps:
(a) provision of a crude radiotracer composition which comprises an 18F-labelled aminoxy functionalized biological targeting moiety (BTM), wherein the BTM is a c-Met binding cyclic peptide which comprises the amino acid sequence:
-Cysa-X1-Cysc-X2-Gly-Pro-Pro-X3-Phe-Glu-Cysd-Trp-Cysb-Tyr-X4—X5—X6—
wherein
X1 is Asn, His or Tyr;
X2 is Gly, Ser, Thr or Asn;
X3 is Tor or Arg;
X4 is Ala, Asp, Glu, Gly or Ser;
X5 is Ser or Thr;
X6 is Asp or Glu;
and Cysa-d are each cysteine residues such that residues a and b as well as c and d are cyclized to form two separate disulfide bonds;
(b) adding a formulation buffer that comprises a radioprotectant at a first concentration to said crude radiotracer composition to give a radiotracer solution which comprises said radiotracer in one or more aqueous water-miscible organic solvent(s) of 5 to 25% v/v organic solvent content;
(c) passing the radiotracer solution from step (b) through a reverse phase SPE cartridge, wherein the radiotracer is retained on said SPE cartridge;
(d) washing the SPE cartridge from step (c) one or more times with a wash solution which comprises an aqueous water-miscible organic solvent(s) solution of a radioprotectant of 15 to 25% v/v organic solvent content;
(e) washing the SPE cartridge from step (d) one or more times with water or aqueous buffer solution;
(f) eluting the washed SPE cartridge of step (d) or (e) with an elution solvent which comprises a radioprotectant in an aqueous ethanol solution having an ethanol content of 35 to 80% v/v, wherein the eluent comprises purified radiotracer in said elution solvent;
wherein each radioprotectant independently comprises one or more of: ascorbic acid, para-aminobenzoic acid; and gentisic acid, and salts thereof with a biocompatible cation.

### Claim 21 (depends on 1)

The method of claim 1, wherein the water-miscible organic solvent of the radiotracer solution comprises acetonitrile.

### Claim 22 (depends on 1)

The method of claim 1, wherein the radiotracer solution of step (b) comprises 0.5 to 5% v/v ethanol.

### Claim 23 (depends on 1)

The method of claim 1, wherein the SPE cartridge is a C18 SPE cartridge.

### Claim 24 (depends on 1)

The method of claim 1, wherein the elution solvent of step (f) comprises 35 to 70% v/v aqueous ethanol.

### Claim 25 (depends on 1)

The method of claim 1, wherein the elution solvent of step (f) comprises 40-60% v/v aqueous ethanol.

### Claim 26 (depends on 1)

The method of claim 1, where the radioprotectant used in the radiotracer solution, wash solution and elution solvent is the same.

### Claim 27 (depends on 1)

The method of claim 1, where the radioprotectant comprises 4-aminobenzoic acid, or a salt thereof with a biocompatible cation.
